Media stories about Juniper Pharmaceuticals (NASDAQ:JNP) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juniper Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.8303538305997 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several research analysts have commented on JNP shares. BMO Capital Markets upgraded shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $31.00 to $34.00 in a research report on Friday, July 14th. ValuEngine downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.00.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded up 1.49% on Tuesday, reaching $4.45. 21,791 shares of the company’s stock traded hands. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $6.40. The company’s 50-day moving average price is $4.57 and its 200 day moving average price is $4.63. The firm has a market cap of $48.26 million, a P/E ratio of 5.75 and a beta of 0.22.
Juniper Pharmaceuticals (NASDAQ:JNP) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The company had revenue of $13.96 million during the quarter, compared to the consensus estimate of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. On average, equities analysts forecast that Juniper Pharmaceuticals will post ($0.39) EPS for the current fiscal year.
WARNING: “Juniper Pharmaceuticals (JNP) Getting Somewhat Favorable Press Coverage, Analysis Shows” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/19/juniper-pharmaceuticals-jnp-getting-somewhat-favorable-press-coverage-analysis-shows.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.